Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
Longxing Cao, Inna Goreshnik, Brian Coventry, et al.
Science (2020) Vol. 370, Iss. 6515, pp. 426-431
Open Access | Times Cited: 594

Showing 26-50 of 594 citing articles:

Recent developments in ultrafiltration membrane technology for the removal of potentially toxic elements, and enhanced antifouling performance: A review
Rouzan Shoshaa, Mohammad Y. Ashfaq, Mohammad A. Al‐Ghouti
Environmental Technology & Innovation (2023) Vol. 31, pp. 103162-103162
Open Access | Times Cited: 41
Transient water wires mediate selective proton transport in designed channel proteins
Huong T. Kratochvil, Laura C. Watkins, Marco Mravic, et al.
Nature Chemistry (2023) Vol. 15, Iss. 7, pp. 1012-1021
Open Access | Times Cited: 39
Advances in developing ACE2 derivatives against SARS-CoV-2
Haoran Zhang, Panjing Lv, Jingrui Jiang, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 5, pp. e369-e378
Open Access | Times Cited: 38
Opportunities and challenges in design and optimization of protein function
Dina Listov, Casper A. Goverde, Bruno E. Correia, et al.
Nature Reviews Molecular Cell Biology (2024) Vol. 25, Iss. 8, pp. 639-653
Closed Access | Times Cited: 35
High-Affinity Peptides for Target Protein Screened in Ultralarge Virtual Libraries
Boyuan Xue, Ruixue Li, Cheng Zhao, et al.
ACS Central Science (2024) Vol. 10, Iss. 11, pp. 2111-2118
Open Access | Times Cited: 25
Preclinical proof of principle for orally delivered Th17 antagonist miniproteins
S. A. Berger, Franziska Seeger, Ta-Yi Yu, et al.
Cell (2024) Vol. 187, Iss. 16, pp. 4305-4317.e18
Open Access | Times Cited: 16
Targeting protein–ligand neosurfaces with a generalizable deep learning tool
Anthony Marchand, Stephen Buckley, Arne Schneuing, et al.
Nature (2025)
Open Access | Times Cited: 1
Deep learning techniques have significantly impacted protein structure prediction and protein design
Robin Pearce, Yang Zhang
Current Opinion in Structural Biology (2021) Vol. 68, pp. 194-207
Open Access | Times Cited: 100
Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19
Suresh Gangadevi, Vishnu Nayak Badavath, Abhishek Thakur, et al.
The Journal of Physical Chemistry Letters (2021) Vol. 12, Iss. 7, pp. 1793-1802
Closed Access | Times Cited: 92
The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies
Anastassios C. Papageorgiou, Imran Mohsin
Cells (2020) Vol. 9, Iss. 11, pp. 2343-2343
Open Access | Times Cited: 87
The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection
Brandon J. Beddingfield, Naoki Iwanaga, Prem P. Chapagain, et al.
JACC Basic to Translational Science (2020) Vol. 6, Iss. 1, pp. 1-8
Open Access | Times Cited: 84
Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2
Ross C. Larue, Enming Xing, Adam D. Kenney, et al.
Bioconjugate Chemistry (2020) Vol. 32, Iss. 1, pp. 215-223
Open Access | Times Cited: 84
De Novo Discovery of High-Affinity Peptide Binders for the SARS-CoV-2 Spike Protein
Sebastian Pomplun, Muhammad Jbara, Anthony J. Quartararo, et al.
ACS Central Science (2020) Vol. 7, Iss. 1, pp. 156-163
Open Access | Times Cited: 81
A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry
Julián Valero, Laia Civit, Daniel M. Dupont, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 50
Open Access | Times Cited: 80
Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
Carlos Cruz‐Teran, Karthik Tiruthani, Morgan D. McSweeney, et al.
Advanced Drug Delivery Reviews (2020) Vol. 169, pp. 100-117
Open Access | Times Cited: 79
An update of anti-viral treatment of COVID-19
Serap Şimşek Yavuz, İpek Komşuoğlu Çelikyurt
TURKISH JOURNAL OF MEDICAL SCIENCES (2021) Vol. 51, Iss. SI-1, pp. 3372-3390
Open Access | Times Cited: 78
Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
Masaud Shah, Bilal Ahmad, Sangdun Choi, et al.
Computational and Structural Biotechnology Journal (2020) Vol. 18, pp. 3402-3414
Open Access | Times Cited: 76
Protein N-myristoylation: functions and mechanisms in control of innate immunity
Bin Wang, Tong Dai, Wenhuan Sun, et al.
Cellular and Molecular Immunology (2021) Vol. 18, Iss. 4, pp. 878-888
Open Access | Times Cited: 76
Human Cathelicidin Inhibits SARS-CoV-2 Infection: Killing Two Birds with One Stone
Cheng Wang, Shaobo Wang, Daixi Li, et al.
ACS Infectious Diseases (2021) Vol. 7, Iss. 6, pp. 1545-1554
Closed Access | Times Cited: 75
Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2–ACE2 Receptor Interactions
Christopher J. Day, Benjamin Bailly, Patrice Guillon, et al.
mBio (2021) Vol. 12, Iss. 2
Open Access | Times Cited: 72
Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display
Alexander Norman, Charlotte Franck, Mary Christie, et al.
ACS Central Science (2021) Vol. 7, Iss. 6, pp. 1001-1008
Open Access | Times Cited: 68
Recent advances in developing small-molecule inhibitors against SARS-CoV-2
Rong Xiang, Zhengsen Yu, Yang Wang, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 4, pp. 1591-1623
Open Access | Times Cited: 68
A plug-and-play platform of ratiometric bioluminescent sensors for homogeneous immunoassays
Yan Ni, Bas J. H. M. Rosier, Eva A. van Aalen, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 68
Disease-drug and drug-drug interaction in COVID-19: Risk and assessment
Devendra Kumar, Neerja Trivedi
Biomedicine & Pharmacotherapy (2021) Vol. 139, pp. 111642-111642
Open Access | Times Cited: 66
Coronavirus entry: how we arrived at SARS-CoV-2
Gary R. Whittaker, Susan Daniel, Jean K. Millet
Current Opinion in Virology (2021) Vol. 47, pp. 113-120
Open Access | Times Cited: 64

Scroll to top